Abzena’s mammalian cell line development platform, AbZelectPRO, has significantly reduced its timelines by >30% and improved its overall protein production levels. The platform now offers biopharma customers the ability to bridge from DNA to research cell bank (RCB) in 10 weeks, producing up to 8g/L of high-performing titres before process development.  As of today, AbZelectPRO will be the CDMO’s standard platform offering for all its customers.   The AbZelectPRO platform combines ProteoNic...